Blood-Based Biomarkers for Early Alzheimer’s Disease Diagnosis in Real-World Settings

ChatGPT and BCI-VR: a new integrated diagnostic and therapeutic perspective for the accurate diagnosis and personalized treatment of mild cognitive impairment

“…MCI serves as a critical transitional stage between normal aging and dementia. Diagnosis involves clinical observation (Rodriguez-Santiago et al, 2024 ), neuroimaging (Chouliaras and O'Brien, 2023 ), biomarkers (An et al, 2024 ; Carpi et al, 2024 ; Kim S. et al, 2024 ; Kim S. K. et al, 2024 ; Perneczky et al, 2024 ; Plassman et al, 2024 ; Wu et al, 2024 ; Zuo et al, 2024 ), and electroencephalography (EEG) (Amato et al, 2024 ; Faghfouri et al, 2024 ; Khatun et al, 2024 ; Rutkowski et al, 2024 ; Sun et al, 2024 ), as well as neuropsychological assessments.…”

Letter to the Editor: “AI and ML in Alzheimer's disease: Transforming early detection and drug development”

“…The lack of consistency in the protocols for gathering, handling, preserving, examining, and documenting blood samples can affect the capacity to reproduce these evaluations of biomarkers. Therefore, we are utilizing AI and ML algorithms to forecast diseases ( Perneczky et al, 2024 ). ML is revolutionizing the drug development process by generating predictive models based on user input.…”